Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AN2 Therapeutics, Inc.ANTX · Entity 1085 | Director · Chief Executive Officer | March 19, 2026 | March 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AN2 Therapeutics, Inc.
Report date March 19, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.91 · Expires 2031-04-29 | Direct | 249,999 |
Reported balance
After 2026-03-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-19 · Grant · Acquired 249,999 · Balance 249,999 F1: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.60 · Expires 2031-04-29 | Direct | 0 |
Reported balance
After 2026-03-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-19 · Disposition to issuer · Disposed 249,999 · Balance 0 F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.91 · Expires 2032-05-11 | Direct | 225,000 |
Reported balance
After 2026-03-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-19 · Grant · Acquired 225,000 · Balance 225,000 F1: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F4: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.28 · Expires 2032-05-11 | Direct | 0 |
Reported balance
After 2026-03-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-19 · Disposition to issuer · Disposed 225,000 · Balance 0 F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F4: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.91 · Expires 2033-02-22 | Direct | 267,650 |
Reported balance
After 2026-03-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-19 · Grant · Acquired 267,650 · Balance 267,650 F1: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F5: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.99 · Expires 2033-02-22 | Direct | 0 |
Reported balance
After 2026-03-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-19 · Disposition to issuer · Disposed 267,650 · Balance 0 F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F5: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
F2: The option is fully vested.
F3: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
F4: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date.
F5: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2026 Filed Mar 23, 2026 23:00 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 267,650 | Not disclosed Strike: $11.99 | Not disclosed |
DisclosureSEC source: 0001193125-26-120192 · ownership.xml · derivative · entry 6 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 267,650 shares Expires 2033-02-22 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F5 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:00 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 267,650 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120192 · ownership.xml · derivative · entry 5 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267,650 Underlying: Common Stock · 267,650 shares Expires 2033-02-22 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F5 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:00 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 225,000 | Not disclosed Strike: $17.28 | Not disclosed |
DisclosureSEC source: 0001193125-26-120192 · ownership.xml · derivative · entry 4 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2032-05-11 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:00 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 225,000 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120192 · ownership.xml · derivative · entry 3 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2032-05-11 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:00 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | Disposition to issuerStock Option (right to buy) · Derivative | 249,999 | Not disclosed Strike: $6.60 | Not disclosed |
DisclosureSEC source: 0001193125-26-120192 · ownership.xml · derivative · entry 2 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 249,999 shares Expires 2031-04-29 F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 23:00 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 249,999 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-120192 · ownership.xml · derivative · entry 1 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,999 Underlying: Common Stock · 249,999 shares Expires 2031-04-29 F1 · derivative.exercise_price: The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. F3 · price: On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 21:36 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 224,500 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001193125-26-064151 · ownership.xml · derivative · entry 5 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,500 Underlying: Common Stock · 224,500 shares Expires 2036-02-19 F6 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 21:36 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 112,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-064151 · ownership.xml · nonDerivative · entry 1 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 368,630 F1 · shares: Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. F2 · balance_after: Includes a balance of (i) 145,250 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025 and (ii) 99,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:46 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | PurchaseCommon Stock | 10,000 | $1.07 | $10,665.00 |
DisclosureSEC source: 0000950170-25-081041 · ownership.xml · nonDerivative · entry 1 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,380 F1 · price: This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.05 to $1.0699 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes (i) 145,250 restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date and (ii) a balance of 99,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of each such date. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:22 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 290,500 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0000950170-25-030041 · ownership.xml · derivative · entry 5 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,500 Underlying: Common Stock · 290,500 shares Expires 2035-02-25 F6 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:22 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 145,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-030041 · ownership.xml · nonDerivative · entry 1 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,380 F1 · shares: Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date. F2 · balance_after: Includes a balance of 99,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of each such date. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 01:51 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | PurchaseCommon Stock | 50,000 | $1.00 | $49,970.00 |
DisclosureSEC source: 0000950170-24-128202 · ownership.xml · nonDerivative · entry 1 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,065,766 F1 · ownership.nature: Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 23:26 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 198,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000164 · form4.xml · derivative · entry 5 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,000 Underlying: Common Stock · 198,000 shares Expires 2034-03-14 F5 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 23:26 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 99,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000164 · form4.xml · nonDerivative · entry 1 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,130 F1 · shares: These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| March 15, 2024 Filed Mar 29, 2024 20:16 UTC Amendment | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantCommon Stock | 99,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000191 · form4.xml · nonDerivative · entry 1 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,130 F1 · shares: Previously reported on a Form 4 filed on March 18, 2024. As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 23:05 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 2,777 | $20.09 | $55,802.43 |
DisclosureSEC source: 0001610717-24-000013 · form4.xml · nonDerivative · entry 1 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,130 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2023. Read SEC document |
| May 15, 2023 Filed May 16, 2023 00:01 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | PurchaseCommon Stock | 10,000 | $5.38 | $53,770.00 |
DisclosureSEC source: 0000899243-23-013012 · doc4.xml · nonDerivative · entry 1 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,015,766 F1 · ownership.nature: Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019. Read SEC document |
| February 23, 2023 Filed Feb 24, 2023 22:36 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 267,650 | $0.00 Strike: $11.99 | $0.00 |
DisclosureSEC source: 0000899243-23-006150 · doc4.xml · derivative · entry 1 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,650 Underlying: Common Stock · 267,650 shares Expires 2033-02-22 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 01:48 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 23 | $15.04 | $345.92 |
DisclosureSEC source: 0000899243-22-035782 · doc4.xml · nonDerivative · entry 2 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,907 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 01:48 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 4,413 | $15.32 | $67,628.34 |
DisclosureSEC source: 0000899243-22-035782 · doc4.xml · nonDerivative · entry 1 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,930 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $15.00 to $15.85. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 01:33 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 10,111 | $15.61 | $157,846.87 |
DisclosureSEC source: 0000899243-22-035472 · doc4.xml · nonDerivative · entry 3 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,907 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 01:33 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 1,255 | $16.38 | $20,558.91 |
DisclosureSEC source: 0000899243-22-035472 · doc4.xml · nonDerivative · entry 2 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,018 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 01:33 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 5,800 | $15.41 | $89,387.86 |
DisclosureSEC source: 0000899243-22-035472 · doc4.xml · nonDerivative · entry 1 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,273 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 01:19 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 2,036 | $16.72 | $34,036.02 |
DisclosureSEC source: 0000899243-22-035311 · doc4.xml · nonDerivative · entry 5 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,907 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 01:19 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 10,167 | $15.90 | $161,705.12 |
DisclosureSEC source: 0000899243-22-035311 · doc4.xml · nonDerivative · entry 4 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,943 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 04, 2022 Filed Nov 8, 2022 01:19 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 8,828 | $15.80 | $139,474.45 |
DisclosureSEC source: 0000899243-22-035311 · doc4.xml · nonDerivative · entry 3 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,110 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 03, 2022 Filed Nov 8, 2022 01:19 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 3,083 | $16.02 | $49,375.79 |
DisclosureSEC source: 0000899243-22-035311 · doc4.xml · nonDerivative · entry 2 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,938 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 03, 2022 Filed Nov 8, 2022 01:19 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 11,082 | $15.67 | $173,682.65 |
DisclosureSEC source: 0000899243-22-035311 · doc4.xml · nonDerivative · entry 1 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,021 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 02, 2022 Filed Nov 3, 2022 00:52 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 1,544 | $15.07 | $23,262.52 |
DisclosureSEC source: 0000899243-22-034840 · doc4.xml · nonDerivative · entry 2 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,907 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 31, 2022 Filed Nov 3, 2022 00:52 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 2,688 | $15.39 | $41,362.68 |
DisclosureSEC source: 0000899243-22-034840 · doc4.xml · nonDerivative · entry 1 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,451 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 28, 2022 Filed Oct 29, 2022 00:27 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 1,683 | $15.09 | $25,392.43 |
DisclosureSEC source: 0000899243-22-034497 · doc4.xml · nonDerivative · entry 2 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,907 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 27, 2022 Filed Oct 29, 2022 00:27 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 924 | $15.36 | $14,189.96 |
DisclosureSEC source: 0000899243-22-034497 · doc4.xml · nonDerivative · entry 1 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,590 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 26, 2022 Filed Oct 27, 2022 01:19 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 1,678 | $15.10 | $25,342.00 |
DisclosureSEC source: 0000899243-22-034294 · doc4.xml · nonDerivative · entry 4 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,907 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 01:19 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 534 | $16.20 | $8,651.81 |
DisclosureSEC source: 0000899243-22-034294 · doc4.xml · nonDerivative · entry 3 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,585 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 25, 2022 Filed Oct 27, 2022 01:19 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 4,272 | $15.69 | $67,020.42 |
DisclosureSEC source: 0000899243-22-034294 · doc4.xml · nonDerivative · entry 2 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,119 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 24, 2022 Filed Oct 27, 2022 01:19 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 2,866 | $16.17 | $46,343.51 |
DisclosureSEC source: 0000899243-22-034294 · doc4.xml · nonDerivative · entry 1 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,391 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 21, 2022 Filed Oct 25, 2022 01:44 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 2,350 | $16.69 | $39,231.84 |
DisclosureSEC source: 0000899243-22-034092 · doc4.xml · nonDerivative · entry 4 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,907 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 21, 2022 Filed Oct 25, 2022 01:44 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 11,601 | $16.29 | $189,008.13 |
DisclosureSEC source: 0000899243-22-034092 · doc4.xml · nonDerivative · entry 3 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,257 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 20, 2022 Filed Oct 25, 2022 01:44 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 31 | $17.15 | $531.50 |
DisclosureSEC source: 0000899243-22-034092 · doc4.xml · nonDerivative · entry 2 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,858 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 20, 2022 Filed Oct 25, 2022 01:44 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | SaleCommon Stock | 7,262 | $16.68 | $121,140.33 |
DisclosureSEC source: 0000899243-22-034092 · doc4.xml · nonDerivative · entry 1 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,889 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 12, 2022 Filed May 17, 2022 01:10 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $17.28 | $0.00 |
DisclosureSEC source: 0000899243-22-018271 · doc4.xml · derivative · entry 1 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2032-05-11 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from March 25, 2022. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | ConversionSeries A Convertible Preferred Stock · Derivative | 4,907 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-012989 · doc4.xml · derivative · entry 2 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,907 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. Read SEC document |
| March 29, 2022 Filed Apr 1, 2022 00:15 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | ConversionCommon Stock | 4,907 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-012989 · doc4.xml · nonDerivative · entry 1 Easom Eric · CIK 0001914503 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.